Texas is trying to turn ibogaine into a state-backed clinical-research project. The headline version, from the UTMB / UTHealth announcement , is a $50 million public push, UTHealth Houston in the lead, UTMB Health as a major partner, and a statewide university-and-hospital network organized under the name IMPACT.
The careful version is more useful. Texas HHS says the state requested proposals under SB 2308 and selected UTHealth Houston as lead institution; Chapter 491 supplies the statutory framework. But the state’s own HHS page also says contract development hit requirements problems around matching funds and intellectual-property / revenue allocation. So the safest current wording is not “patients are enrolling.” It is: Texas has selected and announced the program, while the launch mechanics still need to clear the state’s own requirements.
What Texas has actually announced
Texas Health and Human Services says SB 2308 directed the agency to request proposals for an ibogaine-treatment consortium, and that HHSC selected UTHealth Houston as the lead institution. A UTMB / UTHealth announcement then described a $50 million HHSC award to lead a two-year, multicenter trial effort.
That same institutional announcement names the partnership IMPACT — Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma. The stated targets include addiction, traumatic brain injury, and other behavioral-health conditions. It also calls out a veteran/TBI focus involving UT Austin and Baylor College of Medicine.
The network is broad
The institutions named in the UTMB / UTHealth source include UTHealth Houston, UTMB Health, Texas Tech University, Texas Tech University Health Sciences Center El Paso, UT Austin, UT Health San Antonio, UT Tyler, UT Rio Grande Valley, Texas A&M University, the University of North Texas Health Science Center, Baylor College of Medicine, and JPS Health Network in Dallas.
That is the most interesting part of the story. Texas is not just talking about a single psychedelic clinic. The announced IMPACT network tries to wire ibogaine research into a public-university medical network, with addiction and brain-injury questions sitting beside the usual psychedelic-policy debate.
The caveat matters
The HHS caveat is not a footnote. Texas HHS says contract development began after UTHealth Houston was selected, but that recent plans did not meet Chapter 491 requirements. The problems named by HHS are matching state funds and allocation of intellectual-property and revenue rights.
Chapter 491 is unusually specific. The statute requires a consortium with a drug developer, higher-education institution, and hospital. It also asks for a strategy around FDA approval, participant recruitment, cardiac safety, ibogaine administration, aftercare, data integrity, breakthrough-therapy planning, intellectual property, Texas corporate presence, insurance access, provider credentialing, and financial disclosures verifying nonstate matching funds.
That gives the clean status ladder: authorized by Chapter 491 , selected and contract-development-stage under Texas HHS , and publicly announced through the UTMB / UTHealth release — but not yet safely described as contracted, funded/disbursed, FDA-cleared, enrolling, or running without a newer primary source saying so.
Why it matters
Ibogaine sits in a strange policy position: legally risky in the United States, clinically used in some settings outside it, and repeatedly pulled into conversations about opioid-use disorder, trauma, and brain injury. Texas is now testing whether a state can force a more formal drug-development path around it through Chapter 491’s drug-development framework .
That is worth watching even before a patient is enrolled. The story is not that Texas has solved ibogaine development. The story is that a large state is trying to build the scaffolding for it — and the scaffolding is already exposing the hard parts named in HHS and Chapter 491 : funding match, ownership, FDA strategy, safety, and who gets access if the program works. Texas Tribune and KXAN are useful for the political and roadblock context, but not for overriding the primary-source status caveat.
Source note
Primary sources here are the Texas HHS ibogaine-trials page , Texas Health and Safety Code Chapter 491 , and the UTMB / UTHealth institutional release . Secondary coverage from the Texas Tribune and KXAN is useful for the political and roadblock context, but the HHS page and statute control the current-status language.